Drug Trial Radar · NCT07629960
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
265
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Sep 2029
Study completion Jul 2031
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
Conditions
- Advanced Solid Tumor
- Non-Small Cell Lung Cancer
- Colorectal Neoplasms
- Pancreatic Ductal Adenocarcinoma
Interventions
BLU-924Drug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation and Enrichment: Percentage of Participants with Dose-limiting Toxicity (DLTs)Time frame: Up to 5 years
- Dose Escalation, Enrichment and Expansion: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEsTime frame: Up to 5 years
- Dose Escalation and Enrichment: Maximum Tolerated Dose (MTD) of BLU-924Time frame: Up to 5 years
- Dose Escalation and Enrichment: Recommended Dose for Expansion (RDFE) of BLU-924Time frame: Up to 5 years
- Dose Expansion: Overall Response Rate (ORR)Time frame: Up to 5 years
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists & Research Institute - Sarasota
Sarasota, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Not yet recruiting
Massachusetts General Hospital - Main Campus
Boston, Massachusetts · Not yet recruiting
University of Michigan Medical School Rogel Cancer Center
Ann Arbor, Michigan · Not yet recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Not yet recruiting
NYU Langone Health Perlmutter Cancer Center
New York, New York · Not yet recruiting
Tennessee Oncology, PLLC
Nashville, Tennessee · Not yet recruiting
The University of Texas MD Anderson Cancer Center - Texas Medical Center
Houston, Texas · Not yet recruiting
Next Oncology Virginia Cancer Specialist
Fairfax, Virginia · Recruiting
Mi Cancer Center Barcelona (Pratia Sirius Barcelona)
Barcelona, Catalonia, Spain · Not yet recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Catalonia, Spain · Not yet recruiting
Hospital General Universitrio Gregorio Maranon
Madrid, Madrid, Spain · Not yet recruiting
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain · Not yet recruiting
NEXT Oncology - Madrid
Pozuelo de Alarcón, Madrid, Spain · Not yet recruiting
Clinica Universidad de Navarra (CUN)
Pamplona, Navarre, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.